NASDAQ NMS - GLOBAL MARKET · AGIO
+2.55% · +$0.8700 · Vol 495.9K
Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Biotechnology
$35.03

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is AGIO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Agios Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2013
Employees
540
Country
US

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$34.30
Day high
$35.53
Day low
$34.30
Previous close
$34.16
52W high
$35.53
-1.41% from high
52W low
$28.84
93% of range
Market cap
$2B
EPS
$-6.9500
Shares out
59.5M
Volume
495.9K
VWAP
$35.09
Price history computed in-house
1W
+10.02%
SMA 50 $31.71 · above
SMA 200 $31.71 · above
52W position 93%
Veridion warehouse edge

Warehouse intelligence for AGIO.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

AGIO insider activity

Agios Pharmaceuticals Inc

Score
Coverage building
Pressure
Net selling
Filings
64
Buys / sells
9 / 55
Net value
-$5.7M
Insiders
8
Named filers
BW
Burns James William
Insider
Leadership
GS
Gheuens Sarah
Insider
Leadership
JC
Jones Cecilia
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$5.7M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-04-062026-04-02Burns James WilliamInsidersell$34.713,28049,306$114KSEC Form 4
2026-04-062026-04-02Gheuens SarahInsidersell$34.712,94080,277$102KSEC Form 4
2026-04-062026-04-02Jones CeciliaInsidersell$34.713,14154,998$109KSEC Form 4
2026-04-062026-04-02Milanova TsvetaInsidersell$34.713,26246,829$113KSEC Form 4
2026-04-062026-04-02Viswanadhan KrishnanInsidersell$34.712,95910,282$103KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 59 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

AGIO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AGIO in this window.
Lobbying spend

AGIO lobbying filings, year to date.

Registered lobbying filings matched to Agios Pharmaceuticals Inc.

$110.0K
Refresh interval: 12hSource: LDA disclosure filings
Health IssuesHealth Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
Filing
$70.0K
AGIOS PHARMACEUTICALS

AGIOS PHARMACEUTICALS

Apr 17, 2026
Filing
$20.0K
AGIOS PHARMACEUTICALS

AGIOS PHARMACEUTICALS

Jan 20, 2026
Filing
$10.0K
AGIOS PHARMACEUTICALS INC.

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Apr 20, 2026
Latest news · AGIO
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for AGIO.
Options
Sovereign unlock shows live options positioning for AGIO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.